Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309103045
Category : Medical
Languages : en
Pages : 347
Book Description
In the wake of publicity and congressional attention to drug safety issues, the Food and Drug Administration (FDA) requested the Institute of Medicine assess the drug safety system. The committee reported that a lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the FDA's ability to evaluate and address the safety of prescription drugs after they have reached the market. Noting that resources and therefore efforts to monitor medications' riskâ€"benefit profiles taper off after approval, The Future of Drug Safety offers a broad set of recommendations to ensure that consideration of safety extends from before product approval through the entire time the product is marketed and used.
The Future of Drug Safety
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309103045
Category : Medical
Languages : en
Pages : 347
Book Description
In the wake of publicity and congressional attention to drug safety issues, the Food and Drug Administration (FDA) requested the Institute of Medicine assess the drug safety system. The committee reported that a lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the FDA's ability to evaluate and address the safety of prescription drugs after they have reached the market. Noting that resources and therefore efforts to monitor medications' riskâ€"benefit profiles taper off after approval, The Future of Drug Safety offers a broad set of recommendations to ensure that consideration of safety extends from before product approval through the entire time the product is marketed and used.
Publisher: National Academies Press
ISBN: 0309103045
Category : Medical
Languages : en
Pages : 347
Book Description
In the wake of publicity and congressional attention to drug safety issues, the Food and Drug Administration (FDA) requested the Institute of Medicine assess the drug safety system. The committee reported that a lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the FDA's ability to evaluate and address the safety of prescription drugs after they have reached the market. Noting that resources and therefore efforts to monitor medications' riskâ€"benefit profiles taper off after approval, The Future of Drug Safety offers a broad set of recommendations to ensure that consideration of safety extends from before product approval through the entire time the product is marketed and used.
Prescription Drugs: Improvements Needed in FDA’s Oversight of Direct-to-Consumer Advertising
Author:
Publisher: DIANE Publishing
ISBN: 9781422311578
Category :
Languages : en
Pages : 52
Book Description
Publisher: DIANE Publishing
ISBN: 9781422311578
Category :
Languages : en
Pages : 52
Book Description
From Detached Concern to Empathy
Author: M.D., Ph.D. Jodi Halpern
Publisher: Oxford University Press
ISBN: 0199747717
Category : Medical
Languages : en
Pages : 188
Book Description
Physicians recognize the importance of patients' emotions in healing yet believe their own emotional responses represent lapses in objectivity. Patients complain that physicians are too detached. Halpern argues that by empathizing with patients, rather than detaching, physicians can best help them. Yet there is no consistent view of what, precisely, clinical empathy involves. This book challenges the traditional assumption that empathy is either purely intellectual or an expression of sympathy. Sympathy, according to many physicians, involves over-identifying with patients, threatening objectivity and respect for patient autonomy. How can doctors use empathy in diagnosing and treating patients rithout jeopardizing objectivity or projecting their values onto patients? Jodi Halpern, a psychiatrist, medical ethicist and philosopher, develops a groundbreaking account of emotional reasoning as the core of clinical empathy. She argues that empathy cannot be based on detached reasoning because it involves emotional skills, including associating with another person's images and spontaneously following another's mood shifts. Yet she argues that these emotional links need not lead to over-identifying with patients or other lapses in rationality but rather can inform medical judgement in ways that detached reasoning cannot. For reflective physicians and discerning patients, this book provides a road map for cultivating empathy in medical practice. For a more general audience, it addresses a basic human question: how can one person's emotions lead to an understanding of how another person is feeling?
Publisher: Oxford University Press
ISBN: 0199747717
Category : Medical
Languages : en
Pages : 188
Book Description
Physicians recognize the importance of patients' emotions in healing yet believe their own emotional responses represent lapses in objectivity. Patients complain that physicians are too detached. Halpern argues that by empathizing with patients, rather than detaching, physicians can best help them. Yet there is no consistent view of what, precisely, clinical empathy involves. This book challenges the traditional assumption that empathy is either purely intellectual or an expression of sympathy. Sympathy, according to many physicians, involves over-identifying with patients, threatening objectivity and respect for patient autonomy. How can doctors use empathy in diagnosing and treating patients rithout jeopardizing objectivity or projecting their values onto patients? Jodi Halpern, a psychiatrist, medical ethicist and philosopher, develops a groundbreaking account of emotional reasoning as the core of clinical empathy. She argues that empathy cannot be based on detached reasoning because it involves emotional skills, including associating with another person's images and spontaneously following another's mood shifts. Yet she argues that these emotional links need not lead to over-identifying with patients or other lapses in rationality but rather can inform medical judgement in ways that detached reasoning cannot. For reflective physicians and discerning patients, this book provides a road map for cultivating empathy in medical practice. For a more general audience, it addresses a basic human question: how can one person's emotions lead to an understanding of how another person is feeling?
Selling Sickness
Author: Ray Moynihan
Publisher: Greystone Books
ISBN: 1926706684
Category : Health & Fitness
Languages : en
Pages : 171
Book Description
In this hard-hitting indictment of the pharmaceutical industry, Ray Moynihan and Allan Cassels show how drug companies are systematically using their dominating influence in the world of medical science, drug companies are working to widen the very boundaries that define illness. Mild problems are redefined as serious illness, and common complaints are labeled as medical conditions requiring drug treatments. Runny noses are now allergic rhinitis, PMS has become a psychiatric disorder, and hyperactive children have ADD. Selling Sickness reveals how expanding the boundaries of illness and lowering the threshold for treatments is creating millions of new patients and billions in new profits, in turn threatening to bankrupt national healthcare systems all over the world. This Canadian edition includes an introduction placing the issue in a Canadian context and describing why Canadians should be concerned about the problem.
Publisher: Greystone Books
ISBN: 1926706684
Category : Health & Fitness
Languages : en
Pages : 171
Book Description
In this hard-hitting indictment of the pharmaceutical industry, Ray Moynihan and Allan Cassels show how drug companies are systematically using their dominating influence in the world of medical science, drug companies are working to widen the very boundaries that define illness. Mild problems are redefined as serious illness, and common complaints are labeled as medical conditions requiring drug treatments. Runny noses are now allergic rhinitis, PMS has become a psychiatric disorder, and hyperactive children have ADD. Selling Sickness reveals how expanding the boundaries of illness and lowering the threshold for treatments is creating millions of new patients and billions in new profits, in turn threatening to bankrupt national healthcare systems all over the world. This Canadian edition includes an introduction placing the issue in a Canadian context and describing why Canadians should be concerned about the problem.
Making Medicines Affordable
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Drugs for Life
Author: Joseph Dumit
Publisher: Duke University Press
ISBN: 0822348713
Category : Business & Economics
Languages : en
Pages : 277
Book Description
Challenges our understanding of health, risks, facts, and clinical trials [Payot]
Publisher: Duke University Press
ISBN: 0822348713
Category : Business & Economics
Languages : en
Pages : 277
Book Description
Challenges our understanding of health, risks, facts, and clinical trials [Payot]
Dietary Supplements
Author: United States. Federal Trade Commission. Bureau of Consumer Protection
Publisher:
ISBN:
Category : Advertising
Languages : en
Pages : 32
Book Description
Publisher:
ISBN:
Category : Advertising
Languages : en
Pages : 32
Book Description
Ethical Criteria for Medicinal Drug Promotion
Author: World Health Organization
Publisher:
ISBN:
Category : Business & Economics
Languages : en
Pages : 32
Book Description
"Resolution WHA41.17 adopted by the Forty-first World Health Assembly, 13 May 1988" -- p.1.
Publisher:
ISBN:
Category : Business & Economics
Languages : en
Pages : 32
Book Description
"Resolution WHA41.17 adopted by the Forty-first World Health Assembly, 13 May 1988" -- p.1.
Multilevel and Longitudinal Modeling with IBM SPSS
Author: Ronald H. Heck
Publisher: Routledge
ISBN: 1135074240
Category : Psychology
Languages : en
Pages : 753
Book Description
This book demonstrates how to use multilevel and longitudinal modeling techniques available in the IBM SPSS mixed-effects program (MIXED). Annotated screen shots provide readers with a step-by-step understanding of each technique and navigating the program. Readers learn how to set up, run, and interpret a variety of models. Diagnostic tools, data management issues, and related graphics are introduced throughout. Annotated syntax is also available for those who prefer this approach. Extended examples illustrate the logic of model development to show readers the rationale of the research questions and the steps around which the analyses are structured. The data used in the text and syntax examples are available at www.routledge.com/9780415817110. Highlights of the new edition include: Updated throughout to reflect IBM SPSS Version 21. Further coverage of growth trajectories, coding time-related variables, covariance structures, individual change and longitudinal experimental designs (Ch.5). Extended discussion of other types of research designs for examining change (e.g., regression discontinuity, quasi-experimental) over time (Ch.6). New examples specifying multiple latent constructs and parallel growth processes (Ch. 7). Discussion of alternatives for dealing with missing data and the use of sample weights within multilevel data structures (Ch.1). The book opens with the conceptual and methodological issues associated with multilevel and longitudinal modeling, followed by a discussion of SPSS data management techniques which facilitate working with multilevel, longitudinal, and cross-classified data sets. Chapters 3 and 4 introduce the basics of multilevel modeling: developing a multilevel model, interpreting output, and trouble-shooting common programming and modeling problems. Models for investigating individual and organizational change are presented in chapters 5 and 6, followed by models with multivariate outcomes in chapter 7. Chapter 8 provides an illustration of multilevel models with cross-classified data structures. The book concludes with ways to expand on the various multilevel and longitudinal modeling techniques and issues when conducting multilevel analyses. It's ideal for courses on multilevel and longitudinal modeling, multivariate statistics, and research design taught in education, psychology, business, and sociology.
Publisher: Routledge
ISBN: 1135074240
Category : Psychology
Languages : en
Pages : 753
Book Description
This book demonstrates how to use multilevel and longitudinal modeling techniques available in the IBM SPSS mixed-effects program (MIXED). Annotated screen shots provide readers with a step-by-step understanding of each technique and navigating the program. Readers learn how to set up, run, and interpret a variety of models. Diagnostic tools, data management issues, and related graphics are introduced throughout. Annotated syntax is also available for those who prefer this approach. Extended examples illustrate the logic of model development to show readers the rationale of the research questions and the steps around which the analyses are structured. The data used in the text and syntax examples are available at www.routledge.com/9780415817110. Highlights of the new edition include: Updated throughout to reflect IBM SPSS Version 21. Further coverage of growth trajectories, coding time-related variables, covariance structures, individual change and longitudinal experimental designs (Ch.5). Extended discussion of other types of research designs for examining change (e.g., regression discontinuity, quasi-experimental) over time (Ch.6). New examples specifying multiple latent constructs and parallel growth processes (Ch. 7). Discussion of alternatives for dealing with missing data and the use of sample weights within multilevel data structures (Ch.1). The book opens with the conceptual and methodological issues associated with multilevel and longitudinal modeling, followed by a discussion of SPSS data management techniques which facilitate working with multilevel, longitudinal, and cross-classified data sets. Chapters 3 and 4 introduce the basics of multilevel modeling: developing a multilevel model, interpreting output, and trouble-shooting common programming and modeling problems. Models for investigating individual and organizational change are presented in chapters 5 and 6, followed by models with multivariate outcomes in chapter 7. Chapter 8 provides an illustration of multilevel models with cross-classified data structures. The book concludes with ways to expand on the various multilevel and longitudinal modeling techniques and issues when conducting multilevel analyses. It's ideal for courses on multilevel and longitudinal modeling, multivariate statistics, and research design taught in education, psychology, business, and sociology.
Pharmaceutical Marketing
Author: Brent L. Rollins
Publisher: Jones & Bartlett Publishers
ISBN: 1449626599
Category : Drugs
Languages : en
Pages : 302
Book Description
Publisher: Jones & Bartlett Publishers
ISBN: 1449626599
Category : Drugs
Languages : en
Pages : 302
Book Description